Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Human Immunodeficiency Virus Therapeutics Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, there has been substantial growth in the size of the market for human immunodeficiency virus therapeutics. The market is projected to expand from $14.11 billion in 2024 to $14.94 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. The increase in the historic period can be linked to factors such as a surge in HIV incidence, expansion in awareness campaigns, an upswing in diagnostic testing, growth in the infiltration of generic drugs, and advancement in healthcare infrastructure.
In the upcoming years, the market size of therapies for human immunodeficiency virus is predicted to see substantial growth. It is projected that the size of the market will ascend to $18.57 billion in 2029, with a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period is influenced by factors such as the increasing number of HIV patients, escalated HIV screening, heightened voluntary testing, the rise in unsafe sexual behaviors, and the extension of government initiatives. Key trends during this projection period encompass technological progress, AI-led drug discovery, the advent of long-duration injectable treatments, the incorporation of telemedical services, and the application of CRISPR for gene therapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp
What are the Fundamental Drivers and Innovations Shaping the Human Immunodeficiency Virus Therapeutics Market?
The rising incidence of unsafe sexual behaviors is anticipated to fuel the expansion of the human immunodeficiency virus therapeutics market. Unsafe sexual behaviors are those that do not use barrier protection, heightening the possibility of sexually transmitted infections (STIs) and unwanted pregnancies. A lack of thorough sex education results in limited knowledge about safe methods, leading to increased risk-taking among young people. Human immunodeficiency virus therapeutics aid in reducing the probability of HIV spread from unprotected sexual behaviors by diminishing the viral load to levels that cannot be detected, thus halting the further propagation of the infection. For example, the Centers for Disease Control and Prevention, a US government body, reported in November 2024 that a 2023 survey of U.S high school students found that 32% admitted to having had sexual intercourse at least once and 48% declared that they did not use a condom during their last sexual activity. Consequently, the rising incidence of unprotected sexual behaviors is catalyzing the expansion of the human immunodeficiency virus therapeutics market.
How Is the Human Immunodeficiency Virus Therapeutics Market Segmented?
The human immunodeficiency virus therapeutics market covered in this report is segmented –
1) By Drug Type: Branded Drugs, Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Entry And Fusion Inhibitors, Protease Inhibitors (Pis), Integrase Inhibitors, Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-user: Hospitals And Clinics, Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp
Which Regions Are Driving the Next Phase of the Human Immunodeficiency Virus Therapeutics Market Growth?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Human Immunodeficiency Virus Therapeutics Market?
Key players in the human immunodeficiency virus (HIV) therapeutics market are honing their focus on the creation of advanced treatment methods such as combination therapy. This assures increased treatment efficacy, helps avoid drug resistance and promotes adherence from patients. In this method, multiple therapeutic agents including drugs or treatments are leveraged to manage a particular disease or condition. This not only ensures better efficacy but also reduces side effects and mitigates the risk of drug resistance. Take for instance the case of Gilead Sciences Inc., an American biopharmaceutical company, which in December 2022, gained approval from the U.S. Food and Drug Administration (FDA) for Sunlenca (lenacapavir). This treatment, which is administered in tandem with other antiretroviral medicines, is tailored to aid adults grappling with multi-drug-resistant HIV-1. Interestingly, Sunlenca is the premier and sole HIV treatment that is built upon a capsid inhibitor, offering patients who have undergone extensive treatments a bi-annual dosing option. The approval rests on the success of the CAPELLA trial, noted for its continued virologic suppression efficacy. Sunlenca, with its unique approach to action and long-term formulation, is forecasted to be a major contributor to future HIV treatment and prevention tactics.
View the full report here:
How Is the Human Immunodeficiency Virus Therapeutics Market Defined and What Are Its Core Parameters?
Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies designed to manage and suppress HIV infection, primarily through antiretroviral therapy (ART). These therapeutics help reduce viral load, prevent disease progression to AIDS, and improve the quality of life for individuals living with HIV.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23419
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model